Effects of selenium compounds on proliferation and epigenetic marks of breast cancer cells

Journal of Trace Elements in Medicine and Biology

Volumn 28, Issue 4, 2014, Pages 486-491

  de Miranda, Juliana Xavier ^a   Andrade, Fábia de Oliveira ^a   Conti, Aline de ^a   Dagli, Maria Lúcia Zaidan ^a   Moreno, Fernando Salvador ^a   Ong, Thomas Prates ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Apoptosis; Epigenetic marks; MCF 7 breast cancer cells; Selenium

Indexed keywords

ANTINEOPLASTIC AGENT; DNA METHYLTRANSFERASE 1; METHYLSELENINIC ACID; SELENITE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; EPIGENETICS; GENE EXPRESSION; HISTONE METHYLATION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROCESSING; RASSF1A GENE; TUMOR SUPPRESSOR GENE;

EID: 84912567898     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2014.06.017     Document Type: Article

References (23)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. World Health Organization (WHO), GLOBOCAN 2012: Cancer Incidence and Mortality Worldwide: IARC Cancer Base N°. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: [accessed on 04.12.2013]. http://globocan.iarc.fr/.
2. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159.
3. Verma M., Rogers S., Divi R.L., Schully S.D., Nelson S., Joseph Su L., et al. Epigenetic research in cancer epidemiology: trends, opportunities, and challenges. Cancer Epidemiol Biomarkers Prev 2014, 23:223-233.
4. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007, 8:286-298.
5. Dammann R., Yang G., Pfeifer G.P. Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001, 61:3105-3109.
6. Du L., Xie Z., Wu L.C., Chiu M., Lin J., Chan K.K., et al. Reactivation of RASSF1A in breast cancer cells by curcumin. Nutr Cancer 2012, 64:1228-1235.
7. Ong T.P., Moreno F.S., Ross S.A. Targeting the epigenome with bioactive food components for cancer prevention. J Nutrigenet Nutrigenomics 2011, 4:275-292.
8. Méplan C., Hesketh J. Selenium and cancer: a story that should not be forgotten-insights from genomics. Cancer Treat Res 2014, 159:145-166.
9. Xiang N., Zhao R., Song G., Zhong W. Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells. Carcinogenesis 2008, 29:2175-2181.
10. Chen Y.C., Prabhu K.S., Das A., Mastro A.M. Dietary selenium supplementation modifies breast tumor growth and metastasis. Int J Cancer 2013, 133:2054-2064.
11. Ip C., Thompson H.J., Zhu Z., Ganther H.E. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000, 60:2882-2886.
12. Jeong J., Adamson L.K., Hatam R., Greenhalgh D.G., Cho K. Alterations in the expression and modification of histones in the liver after injury. Exp Mol Pathol 2003, 75:256-264.
13. Andrade F.O., Nagamine M.K., Conti A.D., Chaible L.M., Fontelles C.C., Jordão Junior A.A., et al. Efficacy of the dietary histone deacetylase inhibitor butyrate alone or in combination with vitamin A against proliferation of MCF-7 human breast cancer cells. Braz J Med Biol Res 2012, 45:841-850.
14. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
15. Goldenberg D., Harden S., Masayesva B.G., Ha P., Benoit N., Westra W.H., et al. Intraoperative molecular margin analysis in head and neck cancer. Arch Otolaryngol Head Neck Surg 2004, 130:39-44.
16. Ip C., White G. Mammary cancer chemoprevention by inorganic and organic selenium: single agent treatment or in combination with vitamin E and their effects on in vitro immune functions. Carcinogenesis 1987, 8:1763-1766.
17. Shah Y.M., Al-Dhaheri M., Dong Y., Ip C., Jones F.E., Rowan B.G. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells. Mol Cancer Ther 2005, 4:1239-1249.
18. Suzuki M., Endo M., Shinohara F., Echigo S., Rikiishi H. Differential apoptotic response of human cancer cells to organoselenium compounds. Cancer Chemother Pharmacol 2010, 66:475-484.
19. Lu J., Jiang C., Kaeck M., Ganther H., Vadhanavikit S., Ip C., et al. Dissociation of the genotoxic and growth inhibitory effects of selenium. Biochem Pharmacol 1995, 50:213-219.
20. Davis C.D., Uthus E.O., Finley J.W. Dietary selenium and arsenic affect DNA methylation in vitro in Caco-2 cells and in vivo in rat liver and colon. J Nutr 2000, 130:2903-2909.
21. Davis C.D., Uthus E.O. Dietary selenite and azadeoxycytidine treatments affect dimethylhydrazine-induced aberrant crypt formation in rat colon and DNA methylation in HT-29 cells. J Nutr 2002, 132:292-297.
22. Ramachandran K., Navarro L., Gordian E., Das P.M., Singal R. Methylation-mediated silencing of genes is not altered by selenium treatment of prostate cancer cells. Anticancer Res 2007, 27:921-925.
23. Kassam S., Goenaga-Infante H., Maharaj L., Hiley C.T., Juliger S., Joel S.P. Methylseleninic acid inhibits HDAC activity in diffuse large B-cell lymphoma cell lines. Cancer Chemother Pharmacol 2011, 68:815-821.